Summary A promising new treatment for glioma involves Auger electron emitters such as 1251 or 1231 conjugated to deoxyuridine (lUdR). However, the presence in tumour deposits of non-proliferating cells with clonogenic potential poses a major limitation to this cycle-specific therapy. We have used multicellular tumour spheroids derived from the human glioma cell line UVW to study [1251]1UdR-targeted radiotherapy in aggregates containing cells in different proliferative states. Autoradiographic identification of labelled cells indicated that nuclear incorporation of [1251]1UdR decreased markedly with increasing size of spheroid. IUdR incorporation was maximal in the surface layer of cells and decreased with depth within spheroids. Radiopharmaceutical uptake corresponded closely to the regions of cell cycling as indicated by staining for the nuclear antigen Ki67. The uptake of drug was enhanced by increasing the duration of incubation from 52 h to 104 h. These observations suggest that significant sparing of non-cycling malignant cells would result from treatment delivered as a single injection of radiolabelled lUdR. To achieve maximal therapeutic effect, lUdR should be administered by multiple injections, by slow release from biodegradable implants or by slow-pump delivery.
Glioma constitutes more than 40% of malignancies of the central nervous system and is associated with a very poor prognosis (MacDonald, 1994) . Although this tumour does not metastasize to distant sites, it undergoes diffuse local spread, and total surgical resection with a generous margin of adjacent normal tissue is rarely feasible. It is resistant to most cytotoxic drugs and, while some benefit has been reported with radiation treatment (Leibel et al, 1994) , external beam radiotherapy is limited by normal tissue intolerance. New treatment agents for glioma therapy are therefore urgently needed.
Certain radionuclides, such as 125J and '231, decay by electron capture and internal conversion. Some of the energy of these decay processes is released in the form of low-energy 'Auger' electrons, which have an ultra-short range (< 1 gim) but high linear energy transfer in matter. Therefore, when incorporated into cells, these radionuclides cause maximal damage to cellular components within the immediate vicinity of their site of concentration. Auger electron emitters located on the cell membrane or concentrated in cytoplasm are reported to be relatively non-toxic (Kassis et al, 1987) , whereas DNA-associated Auger electron emitters are highly radiotoxic (Kassis et al, 1987; Desombre et al, 1992) .
Iododeoxyuridine, a thymidine analogue, is preferentially incorporated into the DNA of tumour cells because of their high proliferation rate. It has been exploited as a radiosensitizer for external beam radiotherapy (Kinsella et al, 1988; Miller et al, 1992; Santos et al, 1992) and is also a potential vehicle for the delivery of DNAtargeted Auger electron emitters, such as 1231 or 1251. Compared with non-radiolabelled cytotoxic drugs, which are thought to operate through interaction with DNA, radioiodinated IUdR may be, molecule for molecule, between 1000 and 100 000 times more potent (Humm and Charleton 1989) . The effectiveness of locoregional administration of this agent has been demonstrated in rodent models of gliosarcoma (Kassis, 1994) , meningeal carcinoma and ovarian ascites (Baranowska-Kortylewicz et al, 1991) . As few cells are proliferating in normal brain, treatment with a proliferation-specific agent with high cytotoxic potency should be therapeutically beneficial.
As IUdR is incorporated into the DNA only of those cells in Sphase, a major limitation to the efficacy of the radiopharmaceutical will be the presence of non-dividing cells in the targeted tumour. It is important that the effect of proliferative heterogeneity on IUdRtargeted therapy should be evaluated. Experimental studies on proliferative heterogeneity in relation to DNA-targeted Auger electron therapy have not been reported, although theoretical calculation suggests that this could be the dominant factor in the efficacy of treatment (O'Donoghue and Wheldon, 1996) . Multicellular tumour spheroids are a well-established model of prevascular microtumours that provide a means of studying the intratumour distribution of therapeutic agents and of determining the effect of alternative schedules of administration on cellular incorporation. They have previously been used extensively in targeted therapy research to investigate diffusion gradients of alternative targeting agents (Langmuir et al, 199 1; Mairs et al, 199 1) , to assess efficacies of alternative modalities (Rotmensch et al, 1994) and modulating agents (Langmuir and Medonca, 1992) , to evaluate microdosimetry (Bardies et al, 1992) and to provide experimental model systems for testing hypotheses (Gaze et al, 1992) .
In Spheroid growth and size determination Spheroid growth rates were measured to provide a basis for the selection of incubation times for ['251 ]IUdR labelling. Cultures of spheroids were initiated by inoculating 106 cells into a bacteriological petri dish containing 15 ml of medium. After 2 days' incubation in 95% air and 5% carbon dioxide at 37°C, cell aggregates of approximately 100 ,um diameter were selected and transferred to 24-well plates coated with 1% agar, containing 0.5 ml of medium per well. Each well contained a single aggregate which subsequently grew as a tumour spheroid. The incubation medium was changed once per week. At 2-to 4-day intervals, each spheroid was evaluated by measuring two perpendicular diameters, using an inverted phase-contrast microscope connected to an image analyser. The volume of the spheroids was calculated from the equation:
where a and b are the longest and shortest diameters respectively. Growth kinetic data were fitted (using BMDP program 3R) to a Gompertzian equation, which is defined by the following relationship:
where V(t) and V(0) are the volume of the spheroid at times t and 0, respectively, and A and a are parameters (Figure 1) .
The doubling time of the initial exponential part of the growth curve, calculated as ln2/A, was 52 h. Cell aggregates of approximately 100 jim diameter, grown as described above, were transferred to spinner flasks containing 150 ml of medium. The contents of the vessel were equilibrated with a mixture of 5% carbon dioxide and 95% air for 3 min. The flask was sealed and placed on a magnetic stirrer platform in a warm room at 37°C. Half of the medium was changed three times per week. After 2-6 weeks of growth, spheroids of 150 ,um to 1000 ,um diameter were transferred from the spinner flask into 50-ml tubes, each containing 10 ml of medium with 0.06 MBq ml' ['251]IUdR. Each tube contained 10-20 spheroids, depending on size.
After equilibration with 5% carbon dioxide, the tubes were placed on a roller shaker (Luckham) and incubated at 37°C for either 52 or 104 h, i.e. one or two multiples of the initial volume doubling time calculated as described above. The spheroids were then washed several times in culture medium until no further soluble radioactivity could be eluted. They were embedded in mounting medium on cork discs and frozen by cooling in liquid nitrogen. The time between the end of the incubation period and freezing was 120 min. Sections (5 jim) were cut in a cryostat (Bright) at -20°C and thawed onto silanized slides. After drying at room temperature, the sections were stored desiccated at -20°C.
Ki67 staining Ki67 is a nuclear antigen expressed during the G,, S, G(2 and M phases of the cell cycle, but absent in the Go phase (Gerdes et al, 1983) . Immunocytochemical staining for Ki67 was used to evaluate the growth fraction in monolayers and different sizes of spheroids.
The Ki67 antigen was labelled in spheroid sections and monolayers by a conventional three-step streptavidin-biotin-peroxidase system. Sections were removed from storage, warmed to room temperature and fixed in 1% formaldehyde in PBS. After 3 x 10 min washes in PBS, non-specific binding was blocked with PBS containing 25% swine serum and 25% human serum for 10 min. This was replaced by the primary antibody (Dako or non-immune rabbit immunoglobulins as a negative control, both diluted in PBS containing 10% of each blocking serum. After 1 hour the primary antibody was washed off with three changes of PBS over 15 min. The sections were then incubated for 30 min with a 1:400 dilution British Journal of Cancer (1997) 75(4) of the secondary antibody (Dako), which consisted of biotinylated swine anti-rabbit immunoglobulins in the same diluent. After three washes in PBS over 15 min, the sections were incubated with the streptavidin-biotin-peroxidase complex diluted in PBS for 30 min. After further washes in PBS, the peroxidase signal was developed with a 10-min incubation in 0.05% diaminobenzidine tetrahydrochloride containing 0.01% hydrogen peroxide in PBS.
Autoradiography Following Ki67 staining, slides were dipped in a 1:1 dilution of Kodak NTB-2 emulsion in distilled water at 43°C. After drying, sections were exposed in light-proof desiccating boxes for 92 h. Sections were developed in 1:1 dilution of Kodak D 19 developer at 10°C for 4 min. After a brief wash in distilled water, the emulsion was fixed in Kodafix for 5 min. The slides were washed and counterstained with haematoxylin, dehydrated through graded ethanols and mounted in DPX synthetic resin mountant (BDH Laboratory Supplies). (Figure 2A ), whereas those with a diameter of less than 250 microns had no central necrosis ( Figure 2B ). The diameter of the necrotic core, if present, was measured in an equatorial section in the same manner as the spheroid diameter.
Measurement of lUdR and Ki67 labelling indices
A single observer classed cells as either labelled or unlabelled for LUdR and Ki67. Cells were deemed to be positive for IUdR labelling if there were ten or more silver grains overlying the nucleus. IUdR and Ki67 labelling indices (LIs) were measured by counting the number of labelled nuclei and expressing this as a percentage of the total number of nuclei in predefined regions of the spheroid sections. Both IUdR and Ki67 labelling indices were calculated for either the whole section (in the absence of a necrotic core) or the whole viable rim of tissue (in the presence of a necrotic core). We refer to these values as 'total' labelling indices. Additionally, regional IUdR labelling indices were calculated for concentric tissue layers, consisting of an outer layer extending from the surface of the spheroid to a depth of 25 jim, a middle layer extending from 25 jim to 50 jim and an inner layer extending from 50 jim to 75 jim from the surface. In the small number of sections in which the thickness of the viable rim was less than 75 jim, the inner layer extended from 50 jim to the edge of the necrotic core. Middle Labelling Index A indices, were assessed using the Student's unpaired t-test and paired t-test respectively. RESULTS UVW glioma monolayers in exponential growth showed a Ki67 labelling index of 93% ± 0.65% (s.e.) and an IUdR labelling index of 91% ± 1.29% (s.e.) (mean of eight slide chambers). Figure 3 shows the total IUdR labelling index in spheroids after incubation for 52 and 104 h and the corresponding Ki67 index as a function of spheroid diameter. All labelling indices decreased with increasing spheroid diameter. For spheroids of less than 300 microns diameter, there was no significant difference between the IUdR labelling indices for 52 and 104 h incubation, whereas for larger spheroids the longer incubation time increased labelling. The Ki67 labelling index was greater than both IUdR labelling indices for all sizes of spheroids.
There were strong correlations between the Ki67 and IUdR labelling indices for both 52-and 104-h incubations (r=0.95, P<0.001 and r=0.86, P<0.001 respectively) as shown in Figure 4 . For the shorter period of incubation, the relationship was LI,UdR = 1.09 x LIKi67 -21 and, for the longer period, LIIUCR = 1.08 x LI67 -12. (Sutherland, 1988) . Heterogeneity in tumour metabolism and tumour microenvironment may be important factors responsible for differences in therapeutic sensitivity of tumours (Gorlach and Acker, 1994) . The growth characteristics of spheroids are qualitatively similar to those of solid tumour nodules, which consist of dividing cells close to the capillaries, adjacent non-proliferating cells and more distant necrotic regions (Carlsson and Nederman, 1989) . While the spheroid model represents a simplification of the human glioma in vivo, it may suggest clinical strategies that can be tested in more complex models before introduction into the clinic.
As has been observed for other cell lines (Wheldon et al, 1985; Olea et al, 1992) , UVW glioma spheroids initially grew exponentially but then underwent a progressive reduction in growth rate, and this pattern showed a good fit to a Gompertzian equation. The spheroids developed a necrotic core that was observed when they reached a diameter of 250-300 microns. The rim of viable tissue represented a decreasing proportion of total spheroid volume with increasing spheroid diameter, which partially accounts for the decreasing gradient of the spheroid growth curve.
Other factors that may contribute to limitation of growth include reduced rates of cell division and increased cell death. It has recently been shown that a three-dimensional cellular growth configuration is characterized by an enhanced tendency to apoptosis relative to monolayer cell culture (Rak et al, 1995) . The relative contributions of these factors are of great importance to the potential efficacy and optimal mode of administration of cyclespecific therapy.
The results of the present study indicate that, in this model, there is an inverse relationship between the number of cycling cells, as assessed by Ki67 labelling, and spheroid diameter. Whereas in monolayer culture more than 90% of exponentially growing cells stained positively with Ki67, the growth fraction in the smallest spheroids studied was approximately 70%, and this fraction decreased progressively with increasing spheroid size. For the largest spheroids, only 40% of cells in the viable rim were cycling.
Ki67 labelling provides information about the proportion of cells in cycle, irrespective of phase, at the time of fixation, whereas IUdR is incorporated in DNA only during S-phase. Hence a proportion of any cells in which the cycle time exceeds the duration of incubation with IUdR would be expected to remain unlabelled with IUdR while still expressing the Ki67 antigen. In exponentially growing monolayers, the IUdR and Ki67 labelling indices were essentially equal after incubation with IUdR for one doubling time. This suggests that few cells had a longer cycle time than the average and, hence, that there is little heterogeneity in the duration of the cell cycle in monolayers. (Olea et al, 1992) . The reduction in proliferative activity with depth, like the central necrosis, may be owing to several factors, including decreased availability of oxygen and nutrients and accumulation of metabolic waste products, growth-inhibitory agents and hydrogen ions (Groebe and Mueller-Klieser, 1996) .
Another factor that could, in principle, affect the spatial and temporal variation in labelling index is the rate at which IUdR penetrates the interior of spheroids. Thymidine, of which IUdR is an analogue, diffuses readily through cell membranes and has been shown to penetrate spheroids to a depth of 300 ,um within 1 min (Nederman et al, 1988) . Another halogenated thymidine analogue, BUdR (bromodeoxyuridine), penetrated 390 gm in glioma fragments after 1 h (Morimura et al, 1991) . It is therefore unlikely that limited penetration of IUdR was a significant factor in the present study in which we observed a gradient in labelling index within 75 ,um of the surface of spheroids after a minimum incubation period of 52 h.
Increasing the period of incubation with IUdR from 52 to 104 h increased the proportion of cells that incorporated IUdR in most size classes, although the IUdR labelling index remained lower than the corresponding index for Ki67. The increase in labelling index appeared to be greatest for spheroids of intermediate size, and it is possible that these contained a high proportion of cells with a cycle time between 52 and 104 h. In the smaller spheroids most cycling cells were labelled after the shorter period of incubation, whereas in large spheroids nearly 50% of cycling cells remained unlabelled even after the longer period. It is therefore likely that further prolongation of the incubation time would result in a higher uptake of IUdR in cells which are proliferating less rapidly, such as those in the hypoxic and nutrient-deprived regions of large spheroids.
Measurements of BUdR labelling indices of gliomas in vivo or in excised tumour fragments have generally yielded values much lower than those observed in our spheroid model (Morimura et al, 1991; Hoshino et al, 1992 Hoshino et al, , 1993 Onda et al, 1994) , suggesting that cycle-specific treatment would be of limited benefit as primary therapy. However, these measurements have only been performed in surgically removable portions of tumours, which include areas of necrosis and non-proliferative regions. These measurements tell us nothing about the proliferation of residual tumour, particularly in the period following resection. Glioma growth includes local infiltration and is spread along white matter tracks, and hence the tumour is difficult to excise completely. Following resection, regrowth is rapid (Vertosick et al, 1994) , suggesting that the remaining tissue has a high capacity for the accumulation of cycle-specific drugs. Therefore, the optimal therapeutic application of IUdR is likely to be intra-cavity administration after surgery.
The success of curative targeting strategies is governed by the ability to sterilize all clonogens. Therapeutic regimens must therefore be designed to overcome the limitations imposed by proliferative heterogeneity, including the presence of viable tumour cells which are temporarily out of cycle or cycling very slowly. Such conditions were apparent using this spheroid model in which substantial variation in proliferative fraction was observed. This study clearly demonstrates that increased time of incubation with IUdR partly overcomes this obstacle. Maximal tumour uptake of radioiodinated IUdR is likely to be obtained by prolonged exposure to the drug so that the greatest number of cycling cells will incorporate the Auger emitter. Possible modes of delivery include multiple injection, continuous infusion via osmotic pumps and slow release from biodegradable polymer implants (Brem et al, 1995; Whately et al, 1995) .
A potential consequence of the administration of ['251]IUdR is radiation damage to normal proliferating tissues, such as bone marrow and gut. Also, a considerable portion of [1251]IUdR released from dead malignant cells may be incorporated into other proliferating cells (Porshen et al, 1987) . Therefore a long half-life (60 days in the case of 1251) is an unfavourable characteristic of a therapeutic radionuclide. Fortunately, IUdR deiodinates rapidly in vivo (the half-time of deiodination in blood is less than 5 min (Klecker et al, 1985) ), so that in patients with thyroid blockade the major toxicity is likely to be associated with organs involved in its excretion rather than in tissues with a rapid rate of proliferation. An attractive alternative radioconjugate of deoxyuridine is the Auger electron emitter 123I, which has a half-life of 13.2 h. The therapeutic potential of ['231 ]IUdR has been demonstrated in tumour-bearing rodents (Baranowska-Kortylewicz et al, 1991; , and its pharmacokinetics has been studied in a patient with a low-grade astrocytoma. Forty-eight hours after stereotactic, intralesional injection of ['231 ]IUdR, activity was detected only in tumour, bladder and stomach . However, the effect of varying the duration of administration of radioiodinated IUdR on pharmacokinetics, systemic toxicity and therapeutic index remains to be determined.
It is possible that practical limitations to the duration of therapy will preclude the targeting of every potential clonogen by IUdR therapy alone. Consequently, modification to this promising therapeutic approach must be considered, such as the use of radiohalogen conjugates with longer range emissions which may eradicate adjacent, untargeted cells by crossfire irradiation. Theoretical considerations of proliferative heterogeneity imply that benefit may be obtained from use of both short-range and long-range emitters (e.g. 123I and '3'I) or in a combination of shortrange emitters with external beam irradiation (O'Donoghue and Wheldon, 1996) . The optimal strategy will depend on the magnitude and nature of the proliferative heterogeneity in the target tumour. The next phase of our investigation will be a comparison of alternative means of administration and different radiohaloanalogues, using a rat glioma model.
